EUVIMEDEUVIMED entdecken
Crossref

2441-P: Early Hyperglycemia and Insulin Resistance with Insulin-Like Growth Factor-1 Receptor Inhibitor Therapy

WEI ZHAO, XIUYING ZHANG, LINGLI ZHOU, LINONG JI

Diabetes · 05.06.2026 · 75 (Supplement_1)

DOI: 10.2337/db26-2441-p ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von WEI ZHAO und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction and Objective: Insulin-like growth factor-1 receptor (IGF-1R) inhibitors are effective for thyroid eye disease (TED), but treatment-associated hyperglycemia has emerged as a clinical concern. We aimed to characterize glycemic effects of IGF-1R inhibitor therapy and to explore early monitoring signals.

Methods

We conducted post hoc analyses of a 2:1 randomized, double-masked, placebo-controlled trial with a 12-week delayed-start design of IGF-1R inhibitor IBI311 in 53 participants with TED. HbA1c, glycated albumin (GA), and HOMA-IR were compared with placebo at week 12 using mixed-effects models for repeated measures. Data from both groups were pooled to characterize early glycemic trajectories during therapy.

Results

Baseline characteristics were comparable between groups. At week 12, compared with placebo, IBI311 exhibited greater increases in HbA1c (0.52% vs. 0.08%; difference 0.44% [95% CI 0.24-0.65]) and GA (1.34% vs. -0.05%; difference 1.39% [0.78-2.00]), as well as a higher incidence of glycemic deterioration (HbA1c increase >0.5%; 33.3% vs 5.9%; difference 27.5% [8.4-46.5]). HOMA-IR was also higher with IBI311 (7.00 vs. 2.81; difference 4.19 [2.20-6.18]), with a greater increase from baseline (3.4-fold vs. 1.4-fold; P<0.001). In pooled analyses, GA increased by 1.69% (95% CI 1.19-2.20) at week 6. Changes in GA and HbA1c at week 6 were strongly associated with HbA1c change at week 12 (GA: β=0.32 [0.27-0.38], R²=0.76; HbA1c: β=1.47 [1.27-1.67], R²=0.82). Participants with diabetes history showed pronounced early HOMA-IR increase (5.0-fold, IQR 4.8-5.2) with HOMA-β decrease (59% of baseline, IQR 42-76), whereas glycemically stable participants exhibited modest HOMA-IR increases (2.4-fold, IQR [1.9-3.2]) that stabilized over time.

Conclusion

IGF-1R inhibitor therapy cause early-onset glycemic deterioration associated with insulin resistance. GA, HbA1c, HOMA-IR and HOMA-β early at week-6 were associated with subsequent glycemic deterioration, supporting their relevance as early monitoring signals. Disclosure W. Zhao: None. X. Zhang: None. L. Zhou: None. L. Ji: None.

Zitieren

APA

ZHAO, W., ZHANG, X., ZHOU, L., & JI, L. (2026). 2441-P: Early Hyperglycemia and Insulin Resistance with Insulin-Like Growth Factor-1 Receptor Inhibitor Therapy. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-2441-p

Vancouver

ZHAO W, ZHANG X, ZHOU L, JI L. 2441-P: Early Hyperglycemia and Insulin Resistance with Insulin-Like Growth Factor-1 Receptor Inhibitor Therapy. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-2441-p

BibTeX
@article{ZHAO2026,
  author = {ZHAO, WEI and ZHANG, XIUYING and ZHOU, LINGLI and JI, LINONG},
  title = {2441-P: Early Hyperglycemia and Insulin Resistance with Insulin-Like Growth Factor-1 Receptor Inhibitor Therapy},
  journal = {Diabetes},
  year = {2026},
  volume = {75},
  number = {Supplement_1},
  doi = {10.2337/db26-2441-p}
}
Kostenlos starten →